{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:24:55Z","timestamp":1794201895839,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.02.051","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:55:04Z","timestamp":1772178904000},"page":"883.e1-883.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies"],"prefix":"10.1016","volume":"32","author":[{"given":"Megan M.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-4295","authenticated-orcid":false,"given":"Allen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-1683","authenticated-orcid":false,"given":"Challice","family":"Bonifant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Duke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-0064","authenticated-orcid":false,"given":"Yiouli","family":"Ktena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-0858","authenticated-orcid":false,"given":"Nicolas","family":"Llosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-9454","authenticated-orcid":false,"given":"Jessica D.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Rodenbush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Zambidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2026.02.051_bib0001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.051_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.jtct.2026.02.051_bib0003","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood.V118.21.4151.4151","article-title":"Myeloablative haploidentical bone marrow transplantation with T cell replete grafts and post-transplant cyclophosphamide: results of a phase II clinical trial","volume":"118","author":"Symons","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2026.02.051_bib0004","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.051_bib0005","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.051_bib0006","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2008.203","article-title":"Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases","volume":"42","author":"Brodsky","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2026.02.051_bib0007","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.jtct.2026.02.051_bib0008","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2026.02.051_bib0009","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.051_bib0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.051_bib0011","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.jtct.2026.02.051_bib0012","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.051_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bbmt.2015.08.034","article-title":"Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies","volume":"22","author":"Jacoby","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.051_bib0014","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bmt.2012.187","article-title":"Risk and prognostic factors for acute GVHD based on NIH consensus criteria","volume":"48","author":"Lee","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.02.051_bib0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.051_bib0016","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.051_bib0017","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.16557","article-title":"Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation","volume":"190","author":"Cairo","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.051_bib0018","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/00007890-199704270-00006","article-title":"Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation","volume":"63","author":"Kantrow","year":"1997","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.051_bib0019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.051_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/jgid.jgid_139_21","article-title":"BK polyomavirus hemorrhagic cystitis in hematopoietic cell transplant recipients","volume":"14","author":"Lionel","year":"2022","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.jtct.2026.02.051_bib0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0090-4295(82)90633-1","article-title":"Prevention of cyclophosphamide induced hemorrhagic cystitis","volume":"20","author":"Droller","year":"1982","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.051_bib0022","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jtct.2021.01.017","article-title":"Recovery-based revaccination protocol for pediatric hematopoietic stem cell transplant recipients: revaccination outcomes following pediatric HSCT","volume":"27","author":"Haynes","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.02.051_bib0023","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbmt.2018.01.011","article-title":"Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"24","author":"Kasamon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.051_bib0024","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2020009342","article-title":"A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation","volume":"137","author":"Qayed","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.02.051_bib0025","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors\u2014the ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.051_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3324\/haematol.2011.051714","article-title":"The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AMLBFM 98 study","volume":"97","author":"Klusmann","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jtct.2026.02.051_bib0027","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.bbmt.2018.08.010","article-title":"Bone marrow versus peripheral blood from unrelated donors for children and adolescents with acute leukemia","volume":"24","author":"Keesler","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.051_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13517","article-title":"TCR \u03b1+ \u03b2+ \/CD19+ cell-depleted hematopoietic stem cell transplantation for pediatric patients","volume":"23","author":"Mitchell","year":"2019","journal-title":"Pediatr Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.051_bib0029","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/bloodadvances.2021005492","article-title":"Unrelated donor \u03b1\/\u03b2 T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia","volume":"6","author":"Leahy","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jtct.2026.02.051_bib0030","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2026.02.051_bib0031","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2013.09.003","article-title":"In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial","volume":"19","author":"Koura","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.051_bib0032","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","volume":"9","author":"Hyder","year":"2025","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.02.051_bib0033","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2022-165782","volume":"140","author":"Hoover","year":"2022","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:58:19Z","timestamp":1782745099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726001533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666636726001533"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.051","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}